NCT07242859Recruiting
Rice Bran Supplementation for Radiation-Induced Oral Mucositis in Head and Neck Cancer
Effects of Rice Bran on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer and Its Impact on the Quality of Life
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
This study aims to find out if taking rice bran supplements can help reduce the painful mouth sores (oral mucositis) that often occur in patients with head and neck cancer who receive radiation therapy. The trial will include adult patients undergoing radiation treatment. Participants will be given rice bran supplements during their therapy to see if it can lessen these side effects and improve their overall quality of life.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 15 Jan 2023
- Primary completion date
- 30 Nov 2025
- Lead sponsor
- Christina Milad Lobos
- Diseases
- Head and neck cancer
- NCT number
- NCT07242859
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 15 Jan 2023 to the primary completion date, 30 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving any other approved or investigational anti-cancer agent than those specified in this study.
- Patients who are on drugs that could cause oral lesions or are using anticoagulants.
Other illness
- Patients who have oral lesions unrelated to treatment or cancer,
Other
- Pregnant or breastfeeding female patients
Who the study is looking for
- Male or female patients of age 18 years old tor more
- Patients with squamous cell carcinomas without metastases of other non-head and non-neck tumors.
- Patients undergoing radiotherapy with an ECOG performance status of 0, 1, or 2
- Patients who will receive IMRT delivered as radical or adjuvant therapy with or without concurrent chemotherapy
- Ready to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| German university in cairo Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.